Prioritising clinical studies & regulatory reviews of CBPMs
centreformedicinalcannabis.substack.com
The opening paper in the Decalogue pamphlet is written by Prof Trevor Jones, Chairman | e-Therapeutics Plc and Dr Parveen Bhatarah, Regulatory & Compliance Associate | The Centre for Medicinal Cannabis.
Prioritising Clinical studies and regulatory reviews of CBPMs | Abstract
Unapproved CBMP’s are being used to treat several medical conditions including, neuropathic pain, spasticity associated with multiple sclerosis, AIDS, epilepsy and cancer and chemotherapy-induced nausea. Any approved drugs have been carefully evaluated for safety, efficacy, and quality, and are monitored by the MHRA once they are on the market. However, the use of unapproved cannabis and cannabis-derived products can have unpredictable and unintended effects on human health.
This paper discusses the recent regulatory improvements in the UK , existing barriers to entry and how future regulatory innovation can assist the approval of new CBMP’s and support related R&D.
Prioritising clinical studies & regulatory reviews of CBPMs
Prioritising clinical studies & regulatory reviews of CBPMs
Prioritising clinical studies & regulatory reviews of CBPMs
The opening paper in the Decalogue pamphlet is written by Prof Trevor Jones, Chairman | e-Therapeutics Plc and Dr Parveen Bhatarah, Regulatory & Compliance Associate | The Centre for Medicinal Cannabis.
Prioritising Clinical studies and regulatory reviews of CBPMs | Abstract
Unapproved CBMP’s are being used to treat several medical conditions including, neuropathic pain, spasticity associated with multiple sclerosis, AIDS, epilepsy and cancer and chemotherapy-induced nausea. Any approved drugs have been carefully evaluated for safety, efficacy, and quality, and are monitored by the MHRA once they are on the market. However, the use of unapproved cannabis and cannabis-derived products can have unpredictable and unintended effects on human health.
This paper discusses the recent regulatory improvements in the UK , existing barriers to entry and how future regulatory innovation can assist the approval of new CBMP’s and support related R&D.